Vectus Biosystems Limited (ASX:VBS)
Australia · Delayed Price · Currency is AUD 0.1350
-0.0100 (-6.90%)
Sep 18, 2026, 3:38 PM AEST
Vectus Biosystems Market Cap
Vectus Biosystems has a market cap or net worth of 8.33 million as of September 17, 2026. Its market cap has increased by 160.26% in one year.
Market Cap
8.33M
Enterprise Value
5.36M
Revenue
2.77M
Ranking
n/a
PE Ratio
4.80
Stock Price
0.14
ChartMarket Cap Chart
Since February 23, 2016, Vectus Biosystems's market cap has decreased from 36.22M to 8.33M, a decrease of -77.01%. That is a compound annual growth rate of -12.98%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 18, 2026 | 8.33M | -13.41% |
| Dec 31, 2025 | 9.62M | 134.56% |
| Dec 23, 2024 | 4.10M | -74.31% |
| Dec 29, 2023 | 15.96M | -58.89% |
| Dec 30, 2022 | 38.83M | -15.39% |
| Dec 31, 2021 | 45.89M | 20.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 13, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 17, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 19, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Immuron | 14.21M |
| Ceryvyn Therapeutics | 13.68M |
| Cambium Bio | 13.54M |
| ReNerve | 12.06M |
| AdAlta | 9.64M |
| Invex Therapeutics | 8.64M |
| Bio-Gene Technology | 7.45M |
| Acrux | 6.49M |